ADAR1 enhances HTLV-1 and HTLV-2 replication through inhibition of PKR activity

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Cachat, Anne ^a,b,c,d,e   Alais, Sandrine ^a,b,c,d,e   Chevalier, Alain S ^a,b,c,d,e   Journo, Chloé ^a,b,c,d,e   Fusil, Floriane ^c,d,e,f   Dutartre, Hélène ^a,b,c,d,e   Boniface, Adrien ^a,b,c,d,e,g   Ko, Ling N ^h   Gessain, Antoine ^h   Cosset, François Loïc ^c,d,e,f   Suspène, Rodolphe ^h   Vartanian, Jean Pierre ^h   Mahieux, Renaud ^a,b,c,d,e  

^a Equipe Oncogenèse Rétrovirale   (France)

^b Equipe Labellisée Ligue Nationale Contre le Cancer   (France)

^c CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITÉ LYON 1   (France)

^f Equipe virus enveloppés   (France)

^g Unitéd'Ecophysiologie et Nutrition des Plantes   (France)

^h INSTITUT PASTEUR   (France)

Author keywords

ADAR1; HTLV; Interferon; PKR

Indexed keywords

ADENOSINE DEAMINASE ACTING ON RNA 1 PROTEIN; ALPHA INTERFERON; INTERFERON; PROTEIN KINASE R; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; ADAR1 PROTEIN, HUMAN; ADENOSINE DEAMINASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DNA SEQUENCE; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INHIBITION (PSYCHOLOGY); METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; VIROLOGY;

HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2;

ADENOSINE DEAMINASE; CELLS, CULTURED; EIF-2 KINASE; HOST-PATHOGEN INTERACTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; INHIBITION (PSYCHOLOGY); MOLECULAR SEQUENCE DATA; RNA-BINDING PROTEINS; SEQUENCE ANALYSIS, DNA; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 84934942398     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-014-0093-9     Document Type: Article

References (71)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980, 77:7415-7419.
2. Yoshida M, Miyoshi I, Hinuma Y: Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A 1982, 79:2031-2035.
3. Gessain A, Cassar O: Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012, 3:388.
4. Takatsuki T: Adult T-cell leukemia in Japan. In Topics in Hematology. Edited by Seno STS, Irino S. Amsterdam: Excerpta Medica; 1977:73-77.
5. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G: Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985, 2:407-410.
6. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M: HTLV-I associated myelopathy, a new clinical entity. Lancet 1986, 1:1031-1032.
7. Bartman MT, Kaidarova Z, Hirschkorn D, Sacher RA, Fridey J, Garratty G, Gibble J, Smith JW, Newman B, Yeo AE, Murphy EL: Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection. Blood 2008, 112:3995-4002.
8. Murphy EL, Fridey J, Smith JW, Engstrom J, Sacher RA, Miller K, Gibble J, Stevens J, Thomson R, Hansma D, Kaplan J, Khabbaz R, Nemo G: HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors: the REDS investigators. Neurology 1997, 48:315-320.
9. Anupam R, Doueiri R, Green PL: The need to accessorize: molecular roles of HTLV-1 p30 and HTLV-2 p28 accessory proteins in the viral life cycle. Front Microbiol 2013, 4:275.
10. Bertazzoni U, Turci M, Avesani F, Di Gennaro G, Bidoia C, Romanelli MG: Intracellular localization and cellular factors interaction of HTLV-1 and HTLV-2 Tax proteins: similarities and functional differences. Viruses 2011, 3:541-560.
11. Cachat A, Chevalier SA, Alais S, Ko NL, Ratner L, Journo C, Dutartre H, Mahieux R: Alpha interferon restricts human T-Lymphotropic virus type 1 and 2 De Novo infection through PKR activation. J Virol 2013, 87:13386-13396.
12. Cavallari I, Rende F, Bender C, Romanelli MG, D'Agostino DM, Ciminale V: Fine tuning of the temporal expression of HTLV-1 and HTLV-2. Front Microbiol 2013, 4:235.
13. Feuer G, Green PL: Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2. Oncogene 2005, 24:5996-6004.
14. Higuchi M, Fujii M: Distinct functions of HTLV-1 Tax1 from HTLV-2 Tax2 contribute key roles to viral pathogenesis. Retrovirology 2009, 6:117.
15. Journo C, Bonnet A, Favre-Bonvin A, Turpin J, Vinera J, Cote E, Chevalier SA, Kfoury Y, Bazarbachi A, Pique C, Mahieux R: Human T cell leukemia virus type 2 tax-mediated NF-kappaB activation involves a mechanism independent of Tax conjugation to ubiquitin and SUMO. J Virol 2013, 87:1123-1136.
16. Kannian P, Yin H, Doueiri R, Lairmore MD, Fernandez S, Green PL: Distinct transformation tropism exhibited by human T lymphotropic virus type 1 (HTLV-1) and HTLV-2 is the result of postinfection T cell clonal expansion. J Virol 2012, 86:3757-3766.
17. Meertens L, Chevalier S, Weil R, Gessain A, Mahieux R: A 10-amino acid domain within human T-cell leukemia virus type 1 and type 2 tax protein sequences is responsible for their divergent subcellular distribution. J Biol Chem 2004, 279:43307-43320.
18. Romanelli MG, Diani E, Bergamo E, Casoli C, Ciminale V, Bex F, Bertazzoni U: Highlights on distinctive structural and functional properties of HTLV Tax proteins. Front Microbiol 2013, 4:271.
19. Barbeau B, Mesnard JM: Making sense out of antisense transcription in human T-cell lymphotropic viruses (HTLVs). Viruses 2011, 3:456-468.
20. Zane L, Jeang KT: The importance of ubiquitination and sumoylation on the transforming activity of HTLV Tax-1 and Tax-2. Retrovirology 2012, 9:103.
21. Journo C, Mahieux R: HTLV-1 and innate immunity. Viruses 2011, 3:1374-1394.
22. Samuel CE: ADARs: viruses and innate immunity. Curr Top Microbiol Immunol 2012, 353:163-195.
23. Kim U, Wang Y, Sanford T, Zeng Y, Nishikura K: Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci U S A 1994, 91:11457-11461.
24. Hogg M, Paro S, Keegan LP, O'Connell MA: RNA editing by mammalian ADARs. Adv Genet 2011, 73:87-120.
25. Bass BL: RNA editing and hypermutation by adenosine deamination. Trends Biochem Sci 1997, 22:157-162.
26. Bass BL: RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem 2002, 71:817-846.
27. George CX, Samuel CE: Human RNA-specific adenosine deaminase ADAR1 transcripts possess alternative exon 1 structures that initiate from different promoters, one constitutively active and the other interferon inducible. Proc Natl Acad Sci U S A 1999, 96:4621-4626.
28. George CX, Wagner MV, Samuel CE: Expression of interferon-inducible RNA adenosine deaminase ADAR1 during pathogen infection and mouse embryo development involves tissue-selective promoter utilization and alternative splicing. J Biol Chem 2005, 280:15020-15028.
29. Patterson JB, Samuel CE: Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol Cell Biol 1995, 15:5376-5388.
30. Samuel CE: Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology 2011, 411:180-193.
31. Suspene R, Renard M, Henry M, Guetard D, Puyraimond-Zemmour D, Billecocq A, Bouloy M, Tangy F, Vartanian JP, Wain-Hobson S: Inversing the natural hydrogen bonding rule to selectively amplify GC-rich ADAR-edited RNAs. Nucleic Acids Res 2008, 36:e72.
32. Gelinas JF, Clerzius G, Shaw E, Gatignol A: Enhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinase. J Virol 2011, 85:8460-8466.
33. Taylor DR, Puig M, Darnell ME, Mihalik K, Feinstone SM: New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J Virol 2005, 79:6291-6298.
34. Zahn RC, Schelp I, Utermohlen O, Von Laer D: A-to-G hypermutation in the genome of lymphocytic choriomeningitis virus. J Virol 2007, 81:457-464.
35. Mohamed YM, Bangphoomi N, Yamane D, Suda Y, Kato K, Horimoto T, Akashi H: Physical interaction between bovine viral diarrhea virus nonstructural protein 4A and adenosine deaminase acting on RNA (ADAR). Arch Virol 2014, 159:1735-1741.
36. Li Z, Wolff KC, Samuel CE: RNA adenosine deaminase ADAR1 deficiency leads to increased activation of protein kinase PKR and reduced vesicular stomatitis virus growth following interferon treatment. Virology 2010, 396:316-322.
37. Nie Y, Hammond GL, Yang JH: Double-stranded RNA deaminase ADAR1 increases host susceptibility to virus infection. J Virol 2007, 81:917-923.
38. Gandy SZ, Linnstaedt SD, Muralidhar S, Cashman KA, Rosenthal LJ, Casey JL: RNA editing of the human herpesvirus 8 kaposin transcript eliminates its transforming activity and is induced during lytic replication. J Virol 2007, 81:13544-13551.
39. Iizasa H, Wulff BE, Alla NR, Maragkakis M, Megraw M, Hatzigeorgiou A, Iwakiri D, Takada K, Wiedmer A, Showe L, Lieberman P, Nishikura K: Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem 2010, 285:33358-33370.
40. de Chassey B, Aublin-Gex A, Ruggieri A, Meyniel-Schicklin L, Pradezynski F, Davoust N, Chantier T, Tafforeau L, Mangeot PE, Ciancia C, Perrin-Cocon L, Bartenschlager R, Andre P, Lotteau V: The interactomes of influenza virus NS1 and NS2 proteins identify new host factors and provide insights for ADAR1 playing a supportive role in virus replication. PLoS Pathog 2013, 9:e1003440.
41. Casey JL: RNA editing in hepatitis delta virus. Curr Top Microbiol Immunol 2006, 307:67-89.
42. Casey JL, Bergmann KF, Brown TL, Gerin JL: Structural requirements for RNA editing in hepatitis delta virus: evidence for a uridine-to-cytidine editing mechanism. Proc Natl Acad Sci U S A 1992, 89:7149-7153.
43. Jayan GC, Casey JL: Increased RNA editing and inhibition of hepatitis delta virus replication by high-level expression of ADAR1 and ADAR2. J Virol 2002, 76:3819-3827.
44. Suspene R, Petit V, Puyraimond-Zemmour D, Aynaud MM, Henry M, Guetard D, Rusniok C, Wain-Hobson S, Vartanian JP: Double-stranded RNA adenosine deaminase ADAR-1-induced hypermutated genomes among inactivated seasonal influenza and live attenuated measles virus vaccines. J Virol 2011, 85:2458-2462.
45. Ward SV, George CX, Welch MJ, Liou LY, Hahm B, Lewicki H, De la Torre JC, Samuel CE, Oldstone MB: RNA editing enzyme adenosine deaminase is a restriction factor for controlling measles virus replication that also is required for embryogenesis. Proc Natl Acad Sci U S A 2011, 108:331-336.
46. Cattaneo R, Billeter MA: Mutations and A/I hypermutations in measles virus persistent infections. Curr Top Microbiol Immunol 1992, 176:63-74.
47. Cattaneo R, Schmid A, Eschle D, Baczko K, ter Meulen V, Billeter MA: Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell 1988, 55:255-265.
48. Patterson JB, Cornu TI, Redwine J, Dales S, Lewicki H, Holz A, Thomas D, Billeter MA, Oldstone MB: Evidence that the hypermutated M protein of a subacute sclerosing panencephalitis measles virus actively contributes to the chronic progressive CNS disease. Virology 2001, 291:215-225.
49. Toth AM, Li Z, Cattaneo R, Samuel CE: RNA-specific adenosine deaminase ADAR1 suppresses measles virus-induced apoptosis and activation of protein kinase PKR. J Biol Chem 2009, 284:29350-29356.
50. Clerzius G, Gelinas JF, Daher A, Bonnet M, Meurs EF, Gatignol A: ADAR1 interacts with PKR during human immunodeficiency virus infection of lymphocytes and contributes to viral replication. J Virol 2009, 83:10119-10128.
51. Doria M, Neri F, Gallo A, Farace MG, Michienzi A: Editing of HIV-1 RNA by the double-stranded RNA deaminase ADAR1 stimulates viral infection. Nucleic Acids Res 2009, 37:5848-5858.
52. Phuphuakrat A, Kraiwong R, Boonarkart C, Lauhakirti D, Lee TH, Auewarakul P: Double-stranded RNA adenosine deaminases enhance expression of human immunodeficiency virus type 1 proteins. J Virol 2008, 82:10864-10872.
53. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM: A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
54. Kannagi M, Hasegawa A, Takamori A, Kinpara S, Utsunomiya A: The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases. Front Microbiol 2012, 3:323.
55. Oliere S, Douville R, Sze A, Belgnaoui SM, Hiscott J: Modulation of innate immune responses during human T-cell leukemia virus (HTLV-1) pathogenesis. Cytokine Growth Factor Rev 2011, 22:197-210.
56. Suspene R, Henry M, Guillot S, Wain-Hobson S, Vartanian JP: Recovery of APOBEC3-edited human immunodeficiency virus G-> A hypermutants by differential DNA denaturation PCR. J Gen Virol 2005, 86:125-129.
57. Ko NL, Birlouez E, Wain-Hobson S, Mahieux R, Vartanian JP: Hyperediting of human T-cell leukemia virus type 2 and simian T-cell leukemia virus type 3 by the dsRNA adenosine deaminase ADAR-1. J Gen Virol 2012, 93:2646-2651.
58. Wucherpfennig KW, Hollsberg P, Richardson JH, Benjamin D, Hafler DA: T-cell activation by autologous human T-cell leukemia virus type I-infected T-cell clones. Proc Natl Acad Sci U S A 1992, 89:2110-2114.
59. McMillan NA, Chun RF, Siderovski DP, Galabru J, Toone WM, Samuel CE, Mak TW, Hovanessian AG, Jeang KT, Williams BR: HIV-1 Tat directly interacts with the interferon-induced, double-stranded RNA-dependent kinase, PKR. Virology 1995, 213:413-424.
60. Higuchi M, Single FN, Kohler M, Sommer B, Sprengel R, Seeburg PH: RNA editing of AMPA receptor subunit GluR-B: a base-paired intron-exon structure determines position and efficiency. Cell 1993, 75:1361-1370.
61. Laxminarayana D, Khan IU, O'Rourke KS, Giri B: Induction of 150-kDa adenosine deaminase that acts on RNA (ADAR)-1 gene expression in normal T lymphocytes by anti-CD3-epsilon and anti-CD28. Immunology 2007, 122:623-633.
62. Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O: Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 2010, 28:4177-4183.
63. Delebecque F, Pramberger K, Prevost MC, Brahic M, Tangy F: A chimeric human T-cell lymphotropic virus type 1 with the envelope glycoprotein of Moloney murine leukemia virus is infectious for murine cells. J Virol 2002, 76:7883-7889.
64. Pais-Correia AM, Sachse M, Guadagnini S, Robbiati V, Lasserre R, Gessain A, Gout O, Alcover A, Thoulouze MI: Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat Med 2010, 16:83-89.
65. Kimata JT, Wong FH, Wang JJ, Ratner L: Construction and characterization of infectious human T-cell leukemia virus type 1 molecular clones. Virology 1994, 204:656-664.
66. Shimotohno K, Takahashi Y, Shimizu N, Gojobori T, Golde DW, Chen IS, Miwa M, Sugimura T: Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: an open reading frame for the protease gene. Proc Natl Acad Sci U S A 1985, 82:3101-3105.
67. Halin M, Douceron E, Clerc I, Journo C, Ko NL, Landry S, Murphy EL, Gessain A, Lemasson I, Mesnard JM, Barbeau B, Mahieux R: Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription. Blood 2009, 114:2427-2438.
68. Herbert A, Rich A: The role of binding domains for dsRNA and Z-DNA in the in vivo editing of minimal substrates by ADAR1. Proc Natl Acad Sci U S A 2001, 98:12132-12137.
69. Bonnet MC, Daurat C, Ottone C, Meurs EF: The N-terminus of PKR is responsible for the activation of the NF-kappaB signaling pathway by interacting with the IKK complex. Cell Signal 2006, 18:1865-1875.
70. Journo C, Filipe J, About F, Chevalier SA, Brady JN, Afonso PV, Flynn D, Tangy F, Israël A, Vidalain PO, Mahieux R, Weil R: NRP/Optineurin cooperates with TAX1BP1 to potentiate the activation of NF-kappaB by human T-lymphotropic virus type 1 tax protein. PLoS Pathog 2009, 5:e1000521.
71. Laurent AG, Krust B, Galabru J, Svab J, Hovanessian AG: Monoclonal antibodies to an interferon-induced Mr 68,000 protein and their use for the detection of double-stranded RNA-dependent protein kinase in human cells. Proc Natl Acad Sci U S A 1985, 82:4341-4345.